Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Read More…
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone858-202-4500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.33 billion
Profitability
Miscellaneous
Employees7,300
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable
Illumina (NASDAQ:ILMN) Frequently Asked Questions
What is Illumina's stock symbol?
Illumina trades on the NASDAQ under the ticker symbol "ILMN."
How were Illumina's earnings last quarter?
Illumina, Inc. (NASDAQ:ILMN) posted its earnings results on Thursday, October, 24th. The life sciences company reported $1.93 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.40 by $0.53. The life sciences company had revenue of $907 million for the quarter, compared to analyst estimates of $872.65 million. Illumina had a return on equity of 22.05% and a net margin of 28.14%. The business's revenue was up 6.3% compared to the same quarter last year. During the same period last year, the company earned $1.52 earnings per share. View Illumina's Earnings History.
When is Illumina's next earnings date?
What guidance has Illumina issued on next quarter's earnings?
Illumina issued an update on its FY19 earnings guidance on Thursday, October, 24th. The company provided earnings per share (EPS) guidance of $6.40-6.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.04.
What price target have analysts set for ILMN?
14 Wall Street analysts have issued twelve-month target prices for Illumina's stock. Their forecasts range from $280.00 to $380.00. On average, they anticipate Illumina's share price to reach $331.85 in the next twelve months. This suggests a possible upside of 3.3% from the stock's current price. View Analyst Price Targets for Illumina.
What is the consensus analysts' recommendation for Illumina?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina.
What are Wall Street analysts saying about Illumina stock?
Here are some recent quotes from research analysts about Illumina stock:
- 1. Canaccord Genuity analysts commented, "We don’t believe an ultra-premium multiple is now justified for a company looking to grow +6% on the top and bottom lines, which now seem more vulnerable to large misses. What’s more, we lack visibility to 2020 or 2021 growth rates given a wide range of moving parts. We would look to get more constructive if our concerns prove to be transitory, or if ILMN announces the $100 genome at a price point that would meaningfully accelerate its top line and not add further headwinds to its gross, operating or net income margins. ILMN is working hard to drive down the cost of sequencing to be able to usher in the eagerly awaited $100 genome. DTC troubles. On the call, Illumina CEO Francis deSouza indicated he expects a DTC reacceleration “in the coming years,” which to us doesn’t imply a recovery in 2020." (7/30/2019)
- 2. According to Zacks Investment Research, "Illumina continues to register strong top line growth across the company’s high throughput, mid throughput and low throughput categories. In the last-reported fourth quarter, the company observed strong demand for sequencing and array systems, consumables and services. Meanwhile HiSeq to NovaSeq upgrade cycle is progressing well and NextSeq placements are strong. We are also looking forward to the company's newly-inked Pacific Biosciences deal. In the past year, Illumina has outperformed its industry. However, we note that, Illumina exited the fourth quarter of 2018 on a mixed note with earnings lagging the Zacks Consensus Estimate. HiSeq consumables are continuing with their expected decline. Seasonality in DTC functionality continues to dent Illumina’s microarray sales. Funding issues restrict growth. The company is operating in a tough competitive landscape." (4/2/2019)
Has Illumina been receiving favorable news coverage?
Media headlines about ILMN stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Illumina earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the life sciences company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Illumina.
Are investors shorting Illumina?
Illumina saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,750,000 shares, an increase of 7.4% from the October 31st total of 3,490,000 shares. Based on an average daily volume of 999,400 shares, the days-to-cover ratio is presently 3.8 days. Currently, 2.6% of the company's shares are sold short. View Illumina's Current Options Chain.
Who are some of Illumina's key competitors?
Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).
What other stocks do shareholders of Illumina own?
Who are Illumina's key executives?
Illumina's management team includes the folowing people:
- Mr. Jay T. Flatley, Exec. Chairman (Age 66)
- Mr. Francis A. deSouza, CEO, Pres & Director (Age 48)
- Mr. Sam A. Samad, CFO & Sr. VP (Age 49)
- Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)
- Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 48)
Who are Illumina's major shareholders?
Illumina's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.89%), Nikko Asset Management Americas Inc. (0.51%), Massachusetts Financial Services Co. MA (0.47%), Chevy Chase Trust Holdings Inc. (0.33%), Voya Investment Management LLC (0.32%) and WCM Investment Management LLC (0.29%). Company insiders that own Illumina stock include A Blaine Bowman, Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein and Sam Samad. View Institutional Ownership Trends for Illumina.
Which institutional investors are selling Illumina stock?
ILMN stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., State of New Jersey Common Pension Fund D, Stifel Financial Corp, State of Michigan Retirement System, Robeco Institutional Asset Management B.V., Stephens Investment Management Group LLC, Castleark Management LLC and Gabelli Funds LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein and Sam Samad. View Insider Buying and Selling for Illumina.
Which institutional investors are buying Illumina stock?
ILMN stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., California Public Employees Retirement System, Voya Investment Management LLC, Massachusetts Financial Services Co. MA, Parnassus Investments CA, Ardevora Asset Management LLP and WCM Investment Management LLC. View Insider Buying and Selling for Illumina.
How do I buy shares of Illumina?
Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Illumina's stock price today?
One share of ILMN stock can currently be purchased for approximately $321.20.
How big of a company is Illumina?
Illumina has a market capitalization of $47.22 billion and generates $3.33 billion in revenue each year. The life sciences company earns $826 million in net income (profit) each year or $5.72 on an earnings per share basis. Illumina employs 7,300 workers across the globe.View Additional Information About Illumina.
What is Illumina's official website?
How can I contact Illumina?
Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]
MarketBeat Community Rating for Illumina (NASDAQ ILMN)
MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe ILMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
